Patent World Magazine

Watson and Takeda resolve Actos litigation

UNITED STATES – US generic drugs company Watson Pharmaceuticals has settled its patent litigation with the Japanese firm Takeda Pharmaceuticals over, Takeda’s diabetes drug Actos (pioglitazone). Under the terms of the agreement, Takeda has granted Watson a non-exclusive, royalty-free licence to its patents covering pioglitazone. Watson will be able to launch a generic version of the drug in August 2012. The patents covering the drug expire in 2016, according to the Food and Drug Administration.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, click Log In button.

Copyright © 2024 Maritime Insights & Intelligence Limited. Maritime Insights & Intelligence Limited is registered in England and Wales with company number 13831625 and address 5th Floor, 10 St Bride Street, London, EC4A 4AD, United Kingdom. Lloyd's List Intelligence is a trading name of Maritime Insights & Intelligence Limited.

Lloyd's is the registered trademark of the Society Incorporated by the Lloyd's Act 1871 by the name of Lloyd's.